



Advances in the Use of Nanoparticles for Vaccine Platform Development

Guest Editor:

Prof. Dr. Imran Saleem

School of Pharmacy and
Biomolecular Sciences, Liverpool
John Moores University,
Liverpool L3 3AF, UK

Deadline for manuscript
submissions:

31 October 2024

Message from the Guest Editor

Nanoparticle-based formulations, such as polymeric, virosomes, and lipid nanoparticles, help in the induction of sufficient immune responses. These nanoparticle vaccine platform delivery systems protect vaccine candidates, improve stability, prevent degradation, and offer adjuvant properties enhancing immunogenicity and targeting antigen presenting cells (APCs). Moreover, activation of dendritic cells, tumor immunotherapy, and use of biomimetic nanoparticles open new possibilities for the fight against infectious diseases, cancer, and other complex diseases.

This Special Issue welcomes original research and review articles focusing on the preclinical and clinical development of advanced nanoparticle delivery systems composed of liposomes and lipid-based nanoparticles, polymeric nanoparticles, gold nanoparticles, inorganic nanoparticles, virus-like particles, self-assembled proteins, biomimetic nanoparticles, and other nanoparticles, including carbon-based nanoparticles (carbon nanotubes and graphenes) to trigger specific immune responses and immunological memory for human and veterinary use.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com